A Study Of Larsucosterol In Alcohol-associated Hepatitis
Scottsdale/Phoenix, AZ; Jacksonville, FL
The purpose of this study is to evaluate the safety and efficacy of larsucosterol, as determined by transplant-free survival through Day 90, in participants with severe alcohol-associated hepatitis (AH) with pre-treatment Maddrey Discriminant Function (MDF) score ≥ 32 and MELD scores 21-30, inclusive.